Trial Profile
A Phase II, Randomized Trial of Standard of Care with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Midostaurin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms RADIUS
- Sponsors Novartis
- 07 Dec 2020 Primary endpoint (Relapse Free Survival (RFS)) has not been met.
- 07 Dec 2020 Results published in the Bone Marrow Transplantation.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology